Cargando…

Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations

BACKGROUND AND OBJECTIVES: To investigate the prevalence and trajectories of neuropsychiatric symptoms (NPS) in relation to cognitive functioning in a cohort of β-amyloid–positive (A+) individuals across the Alzheimer disease (AD) clinical spectrum. METHODS: In this single-center observational study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eikelboom, Willem S., van den Berg, Esther, Singleton, Ellen H., Baart, Sara J., Coesmans, Michiel, Leeuwis, Annebet E., Teunissen, Charlotte E., van Berckel, Bart N.M., Pijnenburg, Yolande A.L., Scheltens, Philip, van der Flier, Wiesje M., Ossenkoppele, Rik, Papma, Janne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480405/ https://www.ncbi.nlm.nih.gov/pubmed/34413181 http://dx.doi.org/10.1212/WNL.0000000000012598

Ejemplares similares

Biweekly fluctuations of neuropsychiatric symptoms according to the Neuropsychiatric Inventory: Erratic symptoms or scores?
por: Eikelboom, Willem S., et al.
Publicado: (2022)

The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians
por: Eikelboom, Willem S., et al.
Publicado: (2022)

The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer’s disease: a natural language processing study
por: Eikelboom, Willem S., et al.
Publicado: (2023)

Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis
por: Eikelboom, Willem S., et al.
Publicado: (2022)

Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study
por: Eikelboom, Willem S., et al.
Publicado: (2019)

Research Criteria for the Behavioral Variant of Alzheimer Disease: A Systematic Review and Meta-analysis
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Social cognition deficits and biometric signatures in the behavioural variant of Alzheimer’s disease
por: Singleton, Ellen H, et al.
Publicado: (2022)

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2018)

Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer’s Disease at the Memory Clinic: The BEAT-IT Study
por: Eikelboom, Willem S., et al.
Publicado: (2023)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory
por: de Haan, Willem, et al.
Publicado: (2009)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease
por: Benedictus, Marije R., et al.
Publicado: (2016)

The natural history of primary progressive aphasia: beyond aphasia
por: Ulugut, Hulya, et al.
Publicado: (2021)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

A clinical-radiological framework of the right temporal variant of frontotemporal dementia
por: Ulugut Erkoyun, Hulya, et al.
Publicado: (2020)

Short Digital Spatial Memory Test Detects Impairment in Alzheimer’s Disease and Mild Cognitive Impairment
por: Poos, Jackie M., et al.
Publicado: (2021)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Neuropsychiatric symptoms in patients with possible vascular cognitive impairment, does sex matter?
por: Exalto, LG, et al.
Publicado: (2022)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin?
por: Verfaillie, Sander C. J., et al.
Publicado: (2015)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Amyloid imaging in clinical trials
por: Ossenkoppele, Rik, et al.
Publicado: (2013)

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Precision estimates of relative and absolute cerebral blood flow in Alzheimer’s disease and cognitively normal individuals
por: Heeman, Fiona, et al.
Publicado: (2022)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease
por: Singleton, Ellen H., et al.
Publicado: (2020)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer’s Disease
por: Adriaanse, Sofie M., et al.
Publicado: (2014)

Young‐onset dementia in memory clinics in the Netherlands: Study design and description of PRECODE‐GP
por: van Gils, Aniek M., et al.
Publicado: (2023)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mnmgdb7f7l7lf6vedrjchplfsl